Madrigal Pharmaceuticals has announced that it is investigating a possible link between its new anti-inflammatory treatment for pain and its increased use of synthetic cannabinoids in patients undergoing operations.

The company said in a statement on Monday that it was looking into whether the use of the drug, which is currently in the pipeline, was linked to increased use by doctors of synthetic compounds that have been linked to a variety of health issues, including psychosis, anxiety, depression, and anxiety disorders.

The drug’s development follows its initial announcement in March that it would be moving to a more clinical approach, with a focus on the treatment of pain.

“As part of the ongoing ongoing investigation, Madrigals research and development team has conducted a review of its pipeline of analgesics and cannabinoid compounds,” the statement read.

“The review has identified a possible potential link between the increased use and efficacy of the new compounds and the increase in pain that occurred in patients with chronic pain.”

The statement added that Madrigalia was currently working on a regulatory advisory board, which includes “industry experts” to ensure it is compliant with all relevant laws and regulations.

In the statement, Madriagal said that it had recently conducted a series of studies and interviews with patients and their families, and that “the study results, which were consistent with the patient population, were not significant in relation to adverse effects on the patients.”

The company did not respond to requests for comment from The Associated Press.

In a blog post, Madraigal said it had not received a response to the latest findings, and the company was “still assessing its response to these latest findings.”

The drug has not yet been approved by the U.S. Food and Drug Administration.

It is not clear whether Madrigalian’s investigation was related to the company’s earlier announcement that it planned to move to a clinical approach.

The study was first reported in the New York Times, and The Guardian, citing anonymous sources, reported that Madriagan had begun a new study into the use and safety of the drugs.

The research has not been formally reported.

Madrigali is the second opioid company to announce a crackdown on synthetic opioids after Purdue Pharma, which made a similar announcement last month.

The Wall Street Journal reported that Purdue plans to shut down all of its manufacturing facilities for five years starting in March.

The new crackdown comes amid a resurgence in the use, production, and sale of synthetic opioids, which have grown in popularity as they have been marketed as less addictive and less dangerous than traditional opioids.

A number of states have banned the manufacture, distribution, and use of fentanyl and other synthetic opioids.

In April, the Centers for Disease Control and Prevention reported that synthetic opioids accounted for 1.5% of the opioid overdose deaths in the United States.